Limits...
Design and Evaluation of a Fully Implantable Control Unit for Blood Pumps.

Unthan K, Gräf F, Laumen M, Finocchiaro T, Sommer C, Lanmüller H, Steinseifer U - Biomed Res Int (2015)

Bottom Line: As the number of donor hearts is limited while more and more patients suffer from end stage biventricular heart failure, Total Artificial Hearts become a promising alternative to conventional treatment.In validation tests, the control unit demonstrated a stable operation on TET and battery supply and a safe switching from one supply to the other.The overall mean efficiency is 14% on TET and 22% on battery supply.

View Article: PubMed Central - PubMed

Affiliation: Department of Cardiovascular Engineering, Institute of Applied Medical Engineering, Helmholtz Institute, RWTH Aachen University, 52074 Aachen, Germany.

ABSTRACT
As the number of donor hearts is limited while more and more patients suffer from end stage biventricular heart failure, Total Artificial Hearts become a promising alternative to conventional treatment. While pneumatic devices sufficiently supply the patients with blood flow, the patient's quality of life is limited by the percutaneous pressure lines and the size of the external control unit. This paper describes the development of the control unit of the ReinHeart, a fully implantable Total Artificial Heart. General requirements for any implantable control unit are defined from a technical and medical point of view: necessity of a Transcutaneous Energy Transmission, autonomous operation, safety, geometry, and efficiency. Based on the requirements, a prototype is designed; it incorporates a LiFePo4 battery pack with charger, a rectifier for transcutaneous energy transmission, the motor's driver electronics, and a microcontroller which monitors and controls all functions. In validation tests, the control unit demonstrated a stable operation on TET and battery supply and a safe switching from one supply to the other. The overall mean efficiency is 14% on TET and 22% on battery supply. The control unit is suitable for chronic animal trials of the ReinHeart.

No MeSH data available.


Related in: MedlinePlus

(a) Actual and target position among one pumping cycle and (b) current distribution in the four motor coils.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4637009&req=5

fig9: (a) Actual and target position among one pumping cycle and (b) current distribution in the four motor coils.

Mentions: The position control was tested by comparing the target pusher plate position with the positions measured by the microcontroller (Figure 9). The first half of the pump cycle corresponds to the right systole and left diastole, while the second half corresponds to the left systole and right diastole. The actual position follows the target position with an error of up to 7.5%. Although the error is visible in the middle of the curve, the motor reaches the peak values at the end of the left and right systole and thereby guarantees the complete ejection of the ventricle volume into the arteries.


Design and Evaluation of a Fully Implantable Control Unit for Blood Pumps.

Unthan K, Gräf F, Laumen M, Finocchiaro T, Sommer C, Lanmüller H, Steinseifer U - Biomed Res Int (2015)

(a) Actual and target position among one pumping cycle and (b) current distribution in the four motor coils.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4637009&req=5

fig9: (a) Actual and target position among one pumping cycle and (b) current distribution in the four motor coils.
Mentions: The position control was tested by comparing the target pusher plate position with the positions measured by the microcontroller (Figure 9). The first half of the pump cycle corresponds to the right systole and left diastole, while the second half corresponds to the left systole and right diastole. The actual position follows the target position with an error of up to 7.5%. Although the error is visible in the middle of the curve, the motor reaches the peak values at the end of the left and right systole and thereby guarantees the complete ejection of the ventricle volume into the arteries.

Bottom Line: As the number of donor hearts is limited while more and more patients suffer from end stage biventricular heart failure, Total Artificial Hearts become a promising alternative to conventional treatment.In validation tests, the control unit demonstrated a stable operation on TET and battery supply and a safe switching from one supply to the other.The overall mean efficiency is 14% on TET and 22% on battery supply.

View Article: PubMed Central - PubMed

Affiliation: Department of Cardiovascular Engineering, Institute of Applied Medical Engineering, Helmholtz Institute, RWTH Aachen University, 52074 Aachen, Germany.

ABSTRACT
As the number of donor hearts is limited while more and more patients suffer from end stage biventricular heart failure, Total Artificial Hearts become a promising alternative to conventional treatment. While pneumatic devices sufficiently supply the patients with blood flow, the patient's quality of life is limited by the percutaneous pressure lines and the size of the external control unit. This paper describes the development of the control unit of the ReinHeart, a fully implantable Total Artificial Heart. General requirements for any implantable control unit are defined from a technical and medical point of view: necessity of a Transcutaneous Energy Transmission, autonomous operation, safety, geometry, and efficiency. Based on the requirements, a prototype is designed; it incorporates a LiFePo4 battery pack with charger, a rectifier for transcutaneous energy transmission, the motor's driver electronics, and a microcontroller which monitors and controls all functions. In validation tests, the control unit demonstrated a stable operation on TET and battery supply and a safe switching from one supply to the other. The overall mean efficiency is 14% on TET and 22% on battery supply. The control unit is suitable for chronic animal trials of the ReinHeart.

No MeSH data available.


Related in: MedlinePlus